A new study has identified a higher risk of hair loss among users of Wegovy, Novo Nordisk’s widely used weight-loss drug, compared to those taking an older alternative, Contrave.
While previous clinical trials had already suggested a connection between semaglutide—the active ingredient in Wegovy and the diabetes drug Ozempic—and hair loss, this latest research, conducted by the University of British Columbia, provides further evidence. The study, which has yet to undergo peer review, analyzed data from 16 million patients between 2006 and 2020, comparing 1,926 semaglutide users with 1,348 Contrave users.
Key Findings:
52% Higher Risk: Patients taking semaglutide faced a 52% greater likelihood of hair loss than those on Contrave (bupropion-naltrexone).
Greater Impact on Women: Female semaglutide users had over twice the risk of hair loss compared to women on Contrave. However, the study could not determine if men and women experience different risks due to the small number of male cases.
Unclear Long-Term Effects: Researchers did not track whether hair loss persisted after stopping the drug, highlighting the need for further investigation.
Possible Causes:
Rapid Weight Loss: Semaglutide promotes faster weight reduction than Contrave, which may disrupt the natural hair growth cycle.
Nutrient Deficiencies: Reduced appetite and food intake, particularly a lack of protein, could contribute to hair loss.
Hormonal Changes: Some experts believe semaglutide may cause hormonal shifts linked to hair thinning.
Side Effects Like Vomiting: Frequent vomiting could lead to additional nutrient loss.
The study’s authors caution that those considering semaglutide purely for weight loss should be aware of hair loss as a possible side effect. However, for individuals with diabetes or severe obesity, the benefits may outweigh this risk.
Novo Nordisk responded by reaffirming its confidence in the safety and effectiveness of its GLP-1 medications when used as directed.
Dexcom Receives FDA Warning
In other healthcare news, the FDA issued a warning letter to Dexcom, a manufacturer of continuous glucose monitors, following inspections at its facilities in San Diego and Mesa, Arizona. The agency cited “non-conformities” in quality management and manufacturing processes, though it did not restrict Dexcom’s ability to produce or distribute its devices.
Dexcom stated that it is addressing the FDA’s concerns and remains committed to resolving any outstanding issues. Meanwhile, the company announced the appointment of Renée Galá, COO of Jazz Pharmaceuticals, to its board of directors.
Related Topics:
Does Metformin 500 mg Make You Lose Weight
